Harpreet Singh Wasan
Overview
Explore the profile of Harpreet Singh Wasan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
285
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
Kopetz S, Yoshino T, Van Cutsem E, Eng C, Kim T, Wasan H, et al.
Nat Med
. 2025 Jan;
PMID: 39863775
Encorafenib + cetuximab (EC) is approved for previously treated BRAF V600E-mutant metastatic colorectal cancer (mCRC) based on the BEACON phase 3 study. Historically, first-line treatment of BRAF V600E-mutant mCRC with...
2.
Kopetz S, Murphy D, Pu J, Ciardiello F, Desai J, Van Cutsem E, et al.
Nat Med
. 2024 Sep;
30(11):3261-3271.
PMID: 39313594
The BEACON CRC study demonstrated that encorafenib (Enco)+cetuximab (Cetux)±binimetinib (Bini) significantly improved overall survival (OS) versus Cetux + chemotherapy in previously treated patients with BRAF-V600E-mutant mCRC, providing the basis for...
3.
Lamarca A, Palmer D, Wasan H, Ross P, Ma Y, Arora A, et al.
Lancet Oncol
. 2021 Jul;
22(7):e288-e289.
PMID: 34197751
No abstract available.
4.
Lamarca A, Palmer D, Wasan H, Ross P, Ma Y, Arora A, et al.
Lancet Oncol
. 2021 Apr;
22(5):690-701.
PMID: 33798493
Background: Advanced biliary tract cancer has a poor prognosis. Cisplatin and gemcitabine is the standard first-line chemotherapy regimen, but no robust evidence is available for second-line chemotherapy. The aim of...
5.
Stebbing J, Wasan H
J Clin Oncol
. 2019 Jun;
37(22):1847-1850.
PMID: 31173553
No abstract available.